FLEGAMAX 50 mg /Ml Solution
Prescription review online
A doctor will review your case and decide whether a prescription is medically appropriate.
Talk to a doctor about this medicine
Discuss your symptoms and possible next steps in a quick online consultation.
How to use Flegamax
Contents of the leaflet
- Leaflet attached to the packaging: information for the user
- Flegamax, 50 mg/ml, oral solution
- What is Flegamax and what is it used for
- Important information before using Flegamax
- How to use Flegamax
- Possible side effects
- How to store Flegamax
- Contents of the packaging and other information
Leaflet attached to the packaging: information for the user
Flegamax, 50 mg/ml, oral solution
Carbocisteine
Please read carefully the contents of the leaflet before using the medicine, as it contains
important information for the patient.
This medicine should always be used exactly as described in the patient leaflet or as directed by
the doctor or pharmacist.
- This leaflet should be kept in case it needs to be read again.
- If advice or additional information is needed, the pharmacist should be consulted.
- If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should inform the doctor or pharmacist. See section 4.
- If after 4 to 5 days of use there is no improvement or the patient feels worse, the doctor should be contacted.
Table of contents of the leaflet
- 1. What is Flegamax and what is it used for
- 2. Important information before using Flegamax
- 3. How to use Flegamax
- 4. Possible side effects
- 5. How to store Flegamax
- 6. Contents of the packaging and other information
Not sure if this medicine is right for you?
Discuss your symptoms and treatment with a doctor online.
1. What is Flegamax and what is it used for
The respiratory system consists of the nasal cavity, throat, larynx, trachea, bronchi, forming a
complex system - the bronchial tree, and lungs. Due to various respiratory diseases, secretions
begin to accumulate, the excess of which blocks the airways, causing cough and breathing problems.
This secretion can accumulate in different places, including the nose, sinuses, and bronchi.
Flegamax contains carbocisteine as the active substance, which affects the composition of bronchial
secretions. Carbocisteine makes the secretions less viscous and more fluid, making them easier to
expel from the airways during coughing (mucolytic action).
This medicine is used for symptomatic treatment of respiratory diseases characterized by excessive
production of thick and viscous secretions.
To facilitate the expectoration of accumulated secretions, in addition to using a medicine that thins
secretions, it is also recommended to consume a large amount of fluids (at least 2-3 liters per day).
If after 4 to 5 days of use there is no improvement or the patient feels worse, the doctor should be
contacted.
2. Important information before using Flegamax
When not to use Flegamax
- if the patient is allergic to carbocisteine or any of the other ingredients of this medicine (listed in section 6),
- in asthmatic status,
- if there is an active gastric or duodenal ulcer disease,
- in children under 6 years of age.
Warnings and precautions
Before starting to use Flegamax, the doctor or pharmacist should be consulted:
- if the patient has had a history of ulcer disease.
In case of abundant purulent secretions and fever, as well as in case of chronic bronchitis or lung disease and in patients with reduced ability to expectorate, a doctor's visit is necessary, who may prescribe other medicines.
Treatment of patients with bronchial asthma should be carried out under close medical supervision due to the possibility of bronchospasm. If this symptom occurs, the administration of the medicine should be stopped immediately.
Children
Flegamax is not intended for use in children under 6 years of age.
Flegamax and other medicines
The doctor or pharmacist should be informed about all medicines currently or recently used by the patient, as well as about medicines that the patient plans to take.
During the use of Flegamax, cough suppressants or medicines that reduce bronchial secretion should not be used.
Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects that she may be pregnant, or plans to have a child, she should consult a doctor or pharmacist before using this medicine.
There are no data on the use of carbocisteine in pregnant women.
The use of the medicine is not recommended in pregnant women.
It is not known whether carbocisteine passes into breast milk. The medicine should not be used during breastfeeding.
There are no data on the effect of carbocisteine on fertility.
Driving and operating machinery
No studies have been conducted on the effect of carbocisteine on the ability to drive and operate machinery.
Flegamax contains carmoisine (E 124), methyl parahydroxybenzoate, sodium
The medicine may cause allergic reactions (possible late reactions).
The medicine contains from 7.6 to 8.1 mg of sodium (the main component of table salt) in each ml.
This corresponds to 0.38 to 0.41% of the maximum recommended daily intake of sodium in the diet for adults.
Started taking the medicine and have questions?
Discuss your symptoms and treatment with a doctor online.
3. How to use Flegamax
This medicine should always be used exactly as described in the patient leaflet or as directed by
the doctor or pharmacist. In case of doubt, the doctor or pharmacist should be consulted.
The medicine is for oral use.
15 ml of the medicine contains 750 mg of carbocisteine.
A measuring cup is attached to the packaging, which allows the correct volume of the medicine to be measured.
Recommended dose
Adults and adolescents over 12 years of age:
Initially, a dose of 15 ml of the medicine should be used 3 times a day, and then after the mucolytic effect (thinning of secretions) occurs, the dose should be reduced to 10 ml of the medicine 3 times a day.
Childrenfrom 6 to 12 years of age:
5 ml of the medicine 3 times a day.
In children and adolescents, the daily dose of carbocisteine should not exceed 30 mg/kg body weight.
It is recommended that the child drink water after taking the dose of the medicine.
Without the doctor's recommendation, the medicine should not be used for more than 4 to 5 days.
During treatment, an increased amount of fluids should be consumed.
The medicine should not be used before bedtime. The last dose should be taken no later than 4 hours before bedtime.
Use in children
Flegamax is not intended for use in children under 6 years of age.
Use of a higher than recommended dose of Flegamax
No cases of poisoning have been reported in case of overdose. The most likely symptoms of overdose may be gastrointestinal disorders. There is no antidote.
In case of taking a higher dose of the medicine than recommended, the doctor or pharmacist should be consulted immediately.
Missed dose of Flegamax
A double dose should not be used to make up for a missed dose.
In case of any further doubts related to the use of this medicine, the doctor or pharmacist should be consulted.
4. Possible side effects
Like all medicines, Flegamax can cause side effects, although not everybody gets them.
If the patient experiences any of the following symptoms, they should stop using Flegamax and seek medical help immediately:
- angioedema (severe allergic reaction) with swelling of the skin and/or mucous membranes, e.g. in the face, limbs, joints;
- Stevens-Johnson syndrome (blisters turning into ulcers, on the mucous membranes of the mouth, eyes, genitals).
Side effects with unknown frequency (frequency cannot be estimated from available data):
- headache;
- abdominal pain, diarrhea, gastrointestinal bleeding, nausea, and vomiting;
- allergic skin reactions, including rash, itching, urticaria, drug rash.
Reporting side effects
If any side effects occur, including any side effects not listed in the leaflet, the doctor or pharmacist should be informed. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, more information can be collected on the safety of the use of the medicine.
5. How to store Flegamax
The medicine should be stored out of sight and reach of children.
Store at a temperature below 25°C.
Do not use this medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the given month.
After opening the bottle, the medicine should be used within 24 months.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer used. This will help protect the environment.
6. Contents of the packaging and other information
What Flegamax contains
- The active substance of the medicine is carbocisteine. Each ml of the solution contains 50 mg of carbocisteine.
- The other ingredients are: sodium saccharin, methyl parahydroxybenzoate, raspberry flavor (composition: maltodextrin (from corn), modified starch (E 1450), flavoring substances identical to natural ones, flavoring preparation), carmoisine (E 124), sodium hydroxide, carboxymethylcellulose, purified water, sodium hydroxide, 1N aqueous solution (to adjust pH).
What Flegamax looks like and what the packaging contains
Flegamax is a red, transparent solution.
A PET bottle closed with an aluminum cap, with a measuring cup made of PP with a capacity of 15 ml, in a cardboard box.
The packaging contains 120 ml or 200 ml of oral solution.
Marketing authorization holder
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19
83-200 Starogard Gdański
Manufacturer
Laboratorios Alcalá Farma, S.L.
Avenida de Madrid 82
28802 Alcalá de Henares (Madrid)
Spain
To obtain more detailed information, the local representative of the marketing authorization holder should be contacted:
POLPHARMA Biuro Handlowe Sp. z o.o.
ul. Bobrowiecka 6, 00-728 Warsaw
phone 22 364 61 01
Date of last update of the leaflet:
- Country of registration
- Dosage formSolution, 50 mg/ml
- ATC codeR05CB03
- Active substance
- Prescription requiredNo
- ImporterLABORATORIOS ALCALÁ FARMA, S.L.
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to FlegamaxDosage form: Capsules, 375 mgActive substance: carbocisteinePrescription not requiredDosage form: Syrup, 50 mg/mlActive substance: carbocisteinePrescription not requiredDosage form: Granulate, 2700 mg/sachetActive substance: carbocisteineManufacturer: Laboratorios Alcala Farma, S.L.Prescription not required
Online doctors for Flegamax
Discuss questions about Flegamax, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Get Flegamax Prescription Online
Fill in a 2-min form
Tell us your symptoms, history, and what medicine you're requesting.
Pick a doctor or let us assign
Choose a specialist or we'll match you with the next available doctor.
Doctor reviews your case
Usually within 30 minutes. They may ask follow-up questions via chat.
Collect from any pharmacy
Electronic prescription sent to your email — valid across Spain.
Frequently Asked Questions
Flegamax does not require a prescription in Poland. You can check with a doctor online whether this medicine may be appropriate for your situation.
The active ingredient in Flegamax is carbocisteine. This information helps identify medicines with the same composition but different brand names.
Flegamax is manufactured by LABORATORIOS ALCALÁ FARMA, S.L.. Pharmacy brands and packaging may differ depending on the distributor.
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether Flegamax is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.
You can buy Flegamax in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.
To obtain a prescription, you can use Oladoctor:
Other medicines with the same active substance (carbocisteine) include Auropect Comfort, Auropect, Flegamax Forte. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
